Please check your internet connection and try again.
# Tabvoihe-P (Note: Likely refers to "Tavohep" / Tenofovir Disoproxil Fumarate + Hep-associated regimen)
## Overview
Tabvoihe-P is a fixed-dose combination product containing Tenofovir Disoproxil Fumarate (TDF), typically paired with antiviral agents for the management of chronic Hepatitis B (HBV) and/or HIV-1.
## Primary Indications
Treatment of chronic Hepatitis B virus infection in adults and pediatric patients. Treatment of HIV-1 infection in combination with other antiretroviral agents.
## Adult Dosing
* **Standard Dose:** 300 mg (TDF component) orally once daily.
* **Maximum Dose:** 300 mg daily.
## Pediatric Dosing
* **Adolescents (≥12 years and ≥35 kg):** 300 mg orally once daily.
* **Children (<12 years):** Dosing is weight-based. Consult the specific product labeling or pediatric ID guidelines (typically 8 mg/kg once daily up to 300 mg).
## Dose Adjustments
* **Renal Impairment:** Requires adjustment based on Creatinine Clearance (CrCl).
* CrCl 30–49 mL/min: 300 mg every 48 hours.
* CrCl <30 mL/min or hemodialysis: Not recommended.
* **Hepatic Impairment:** No dose adjustment necessary for mild-to-moderate impairment. Safety not established in severe impairment.
## Contraindications
Hypersensitivity to any component of the formulation. Concurrent use with other drugs containing tenofovir.
## Adverse Effects
* **Common:** Nausea, diarrhea, headache, fatigue, dizziness.
* **Serious:** Lactic acidosis/severe hepatomegaly with steatosis (rare but life-threatening), new-onset or worsening renal impairment (Fanconi syndrome), and decreases in bone mineral density (osteomalacia).
## Key Drug Interactions
* **Nephrotoxic Agents:** Avoid concurrent use with aminoglycosides, NSAIDs, or high-dose loop diuretics due to increased risk of renal toxicity.
* **HIV Protease Inhibitors:** TDF may increase concentrations of atazanavir or darunavir; monitoring for toxicity is required.
* **Didanosine:** Concurrent use increases didanosine levels; monitor closely for didanosine-associated toxicities (e.g., pancreatitis).
## Monitoring
* Baseline and periodic monitoring of serum creatinine, estimated CrCl, and serum phosphorus.
* Baseline and periodic monitoring of liver function tests (LFTs) and HBV DNA/HIV viral load.
* Bone mineral density screening in patients with a history of pathologic bone fractures or risk factors for osteoporosis.
## Clinical Pearls
* TDF can cause a reduction in bone mineral density; consider supplementation with Vitamin D and calcium if clinically indicated.
* Assess for occult renal insufficiency before starting therapy; monitor urine glucose and protein in patients at risk for Fanconi syndrome.
* Do not discontinue therapy abruptly in patients with HBV, as this may result in severe acute exacerbations of hepatitis.
***
**Educational Disclaimer:** This information is for educational purposes only. Always consult the latest package insert, clinical guidelines, or an institutional pharmacist to verify current dosing, contraindications, and drug interaction profiles before prescribing or administering medication.
